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gp 140, the CSd/EBV receptor (CR2), is a specific marker of human B lymphocytes. Very recent data suggest 
that CR2 is a membrane site involved in early B cell activation. These properties of CR2 led us to analyze 
the molecular events associated with gp 140. We analyzed whether in some conditions of B lymphocyte acti- 
vation, CR2 could be phospho~lated. We have found that when highly enriched peripheral B cells were 
cultured for 48 h with anti-p Ab and/or SAC, in order to provide an optimal activating signal, phosphoryla- 
Complement receptor 
1. INTRODUCTION 
gp 140 was originally isolated [l] as the C3 
tion of the CR2 was induced. _
-- _. - 
Virus receptor C3d Epstein-Barr virus Phosphorylation B lymphocyte 
Lymphocyte activation 
receptor of the human B lymphoma cell line, Raji, 
and identi~ed as a membrane C3b binding compo- 
nent [1,2], although the part of the C3b molecule 
involved in the gp 140~C3b interaction was not 
determined. Later gp 140 was described as carrying 
a C3d receptor activity [3]. Further molecular 
analysis showed that gp 140 binds to the C3d site 
expressed on the C3d, C3dg and C3bi fragments, 
and to a lesser extent on the C3b fragment [4]. 
*To whom correspondence should be addressed 
~bb~e~iat~ons~ gp 140, 140 kDa membrane glycopro- 
tein; C3, native third component of complement; C3b, 
175 kDa fragment of trypsin cleaved C3; C3d, the 33 
kDa fragment of C3; EBV, Epstein-Barr virus; CR2, C3 
receptor type 2, B cell receptor specific for C3d. C3dg, 
Cfbi+ C3b; BCGF, B cell growth factor; SAC, Staphy- 
tococcus aweus of the Cowan I strain; anti-/c Ab, anti 
IgM antibodies; sIgG, surface immunoglobu~ns; SDS- 
PAGE, SDS-polyacrylamide gel electrophoresis; NP-40, 
Nonidet P-40 
Thus, gp 140 is the human C3d receptor (CR2) 
which is a specific marker of human B 
lymphocytes. 
gp 140, the CR2, is recognized by the polyclonal 
antibodies prepared against the highly purified 
receptor [3] but also by some monoclonal an- 
tibodies such as B2 [5,6], HB-5 [7,8] and OKB-7 
[9, lo] prepared randomly against he whole B lym- 
phocytes. 
CR2 was also found, by us [ll] and others 19, 
121, to be the EBV receptor. Meanwhile, we have 
found that F(ab)‘2 anti-gp 140 enhances, in the 
presence of BCGF, the proliferation of peripheral 
human B lymphocytes [ 131. Taken together, these 
data lend support to CR2 being a specific mem- 
brane site involved in early B cell activation in 
synergy with other membrane and/or intracellular 
events induced by growth factors such as BCGF or 
by multipotent agents such as EBV. Such functions 
of CR2 led us to analyze the molecular events 
associated with gp 140. Thus, among all the puta- 
tive properties of CR2 involved in B cell activation, 
phosphorylation of this receptor needs to be 
analyzed. 
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Here we attempted to determine whether phos- 
phorylation of CR2 could be induced in human B 
lymphocytes. We have found that gp 140, the CR2, 
is phosphorylated upon in vitro activation of 
peripheral B lymphocytes. 
2. MATERIALS AND METHODS 
2.1. Cells 
Blood was drawn from healthy volunteers and 
peripheral blood mononuclear cells were isolated 
by centrifugation on Ficoll-Hypaque (Pharmacia). 
B enriched cells were prepared by two successive 
cycles of E-rosette-forming cell depletions using 
aminoethylisothiouronium bromide hydrobromide 
(AET)-treated sheep erythrocytes and one cycle of 
plastic adherence. The resulting preparations re- 
presented about 5% of the initial mononuclear 
cells and will be referred to as highly enriched B 
cells. They contained more than 70% membrane 
Ig+ cells, 5-15% peroxidase-positive cells and less 
than 0.5% E-rosette-forming cells or T3+ cells (us- 
ing 0KT3 monoclonal antibody, Ortho Pharma- 
ceutics, Raritan, NJ). They did not proliferate 
when stimulated with various concentrations of 
phytohemagglutinin. 
2.2. Activation of B lymphocytes 
50 x lo6 highly enriched B cells were cultured for 
48 h in RPM1 1640 medium containing 2-mercap- 
toethanol and 10% fetal bovine serum in a final 
volume of 24 ml without stimulus or with lOpg/ml 
of immobilized anti-p Ab (BioRad) and/or SAC 
(l/10000 final concentration). 
2.3. Ph~sphorylffti~n of human B lymphocytes 
Phosphorylation was performed as described by 
Pober et al. [14]. Briefly, B lymphocytes (50 x 106) 
were incubated for 1 h at 37°C in buffer A (150 
mM NaCl, 5 mM MgCL, 5 mM KCl, 2 mM L- 
glutamine, 1.8 mM glucose, 10 mM Tris, pH 7.4) 
to deplete cells of Pi. Cells were pelleted then in- 
cubated in the presence of 5 mCi 32P (185 MBq, 
Amersham) in 1 ml buffer A for 2 h at 37°C. 
2.4. Cell membrane extract 
Cells were extensively washed in phosphate buf- 
fered saline (PBS), pH 7.4. Then cells were lyzed 
by the addition of 3 x 10m4 M barbital buffer (pH 
7.4) at 4°C and membranes collected by centri- 
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fugation at 1~~~ g for 30 min at 4°C. Mem- 
brane proteins were washed 3 times in the same 
buffer then solubilized with 1% NP-40 (Fluka) in 
barbital buffer (0.04 mM, pH 7.4) at 4°C for 45 
min. Insoluble material was removed by centri- 
fugation for 60 min at 100 000 x g at 4°C. The pro- 
tein content of the solubilized membranes was 
estimated by the Bradford assay [lS]. 
2.5. Immunoprecipitation 
Solubilized membrane extracts were precleared 
by absorption on 50 mg Seph~ose-protein A 
(Pharmacia) preloaded with 4 mg IgG of a rabbit 
preimmune serum for 1 h at 4°C. Effluent was ab- 
sorbed for 2 h at 4°C on 15 mg Sepharose-protein 
A preloaded successively with rabbit IgG fraction 
of anti-mouse Ig (Dako, Denmark), then with 50~1 
of the monoclon~ OKB-7 (Ortho), an anti-CR2 
[4,9,10]. Elution was performed with sample buf- 
fer (62.5 mM Tris, 1% SDS, 10% glycerol, pH 6.8) 
containing 2-mercaptoethanol. 
2.6. SDS-PAGE 
SDS-PAGE was performed according to Laem- 
mli [16] on a 10% polyacrylamide gel. Gels were 
washed extensively by 1 M NaOH, to remove the 
32Pi non-covalently bound to membrane com- 
ponents. Then, gels were autoradiographed using 
Trimax XD films with intensifying screens. 
3. RESULTS AND DISCUSSION 
It is well established that the binding of anti-,u 
Ab with the sIgGs receptor and/or their crosslink- 
ing with agents such as SAC induce biochemical 
events which lead to B cell activation [17,18]. To 
provide an optimal activating signal for B lym- 
phocytes, preparations of highly enriched B cells 
were cultured for 48 h with anti-p Ab and SAC 
added together or separately. B cells cultured in the 
absence of these reagents were used as controls. 
After this step of activation, 50x lo6 cells were 
washed, depleted in inorganic phosphate and in- 
cubated with 32P for 2 h at 37°C. Then cells were 
extensively washed and membranes prepared. 
Membrane components were solubilized in 1% 
NP-40 in barbital buffer, pH 7.4. Solubilized 
membrane components were submitted either 
directly to gel electrophoresis analysis or to im- 
munoprecipitation with a monoclonal anti-CR2. 
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Fig. 1. Analysis by SDS-PAGE of 32P-labeled membrane 
components solubilized from human peripheral B lym- 
phocytes. 50x lo6 cells, non-activated or activated by 
anti-p Ab and/or SAC during 48 h, were labeled by 5 
mCi of 32Pi for 2 h at 37°C. Membranes were prepared 
then membrane components were solubilized by 1% 
NP-40. Panel A (lanes): 20 ~1 crude extract from non- 
activated (1) and anti-p Ab and/or SAC activated (2) B 
lymphocytes were subjected to gel electrophoresis. Panel 
B (lanes): solubilized membrane extracts from non- 
activated (1) or anti-p Ab and/or SAC activated (2) B 
lymphocytes were precleared by absorption on Sepharose- 
protein A preloaded with IgG fraction of a rabbit preim- 
mune serum for 1 h at 4°C. Effluent was absorbed on 
Sepharose-protein A preloaded successively with rabbit 
IgG fraction of anti-mouse Ig and then with a mono- 
clonal anti-CR2, OKB-7. Elution was performed with 
sample buffer containing 2-mercaptoethanol. A control 
was performed from activated B lymphocyte extract by 
measuring the eluate obtained from Sepharose-protein A 
loaded only with rabbit IgG fraction of anti-mouse Ig 
(3). Samples were run on a 10% polyacrylamide gel and 
analyzed by autoradiography. 
As shown in fig.1, phosphorylation of solubi- 
lized membrane components occurred in non-acti- 
vated and in anti-p Ab and/or SAC activated B 
lymphocytes (fig.lA). However, when the same 
amount of solubilized membrane proteins was 
analyzed in the same conditions, i.e. gel elec- 
trophoresis and autoradiogram analysis during the 
same exposure time, membrane components solu- 
bilized from anti-p AB and/or SAC activated B 
lymphocytes were found to be more intensively 
labeled (fig.lA). This is supported also by the ratio 
of trichloroacetic acid-precipitable 32P radioactivi- 
ty to solubilized membrane proteins which was 
higher in activated B lymphocytes (not shown). 
When CR2, the C3d/EBV receptor, was 
immunoprecipitated from membrane extracts of 
non-activated or activated B lymphocytes, using 
the monoclonal OKB-7, which reacts with gp 140 
(4,9,10], phosphorylation of this receptor was 
detected only in B lymphocytes activated by anti-p 
Ab and/or SAC (fig.lB, lane 2) but not in non- 
activated B lymphocytes (lane 1). Such 
phosphorylation is associated with gp 140 even 
after NaOH treatment of the gels, supporting a 
covalent binding. Thus, these data support strong- 
ly the evidence that CR2, the C3d/EBV receptor, 
could be phosphorylated in peripheral B lym- 
phocytes activated in vitro by anti-p Ab and/or 
SAC, two agents which crosslink slgGs [17,18]. 
From these data, it appears that phosphoryla- 
tion of membrane components is higher in anti-p 
Ab and/or SAC activated peripheral B lympho- 
cytes than in non-activated B cells. Very likely, 
these effecters activate protein kinase activities. 
Phosphorylations induced by anti-p Ab and/or 
SAC are not specific for CR2, as many other mem- 
brane proteins are labeled. Other membrane recep- 
tors have also been reported to be phosphorylated 
in activated human cells [ 19,201. 
It is more likely that the Pi labeling of CR2 is 
mediated through an intracellular high-energy 
phosphorylated intermediate (e.g. ATP). We can- 
not rule out the possibilities that phosphorylation 
of CR2 is mediated either by some phosphate 
donor transported and utilized in the extracellular 
space or that an intracellular phosphorylation has 
taken place on an extracellular esidue or a phos- 
pholipid associated with CR2. Amino acid se- 
quence analysis of CR2 will resolve this question. 
However, it is more likely that an intracellular 
355 
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residue of gp 140 is phosphorylated upon B cell ac- 
tivation. In such a hypothesis, CR2 would be a 
transmembrane receptor, like human histocom- 
patibility antigens [ 141. Such a transmembrane 
conformation would be involved in transmission 
of post-membrane signals, in direct or indirect 
CR2- enzyme and/or CR2-cytoskeletal interac- 
tions. Indeed, different proteins that bind to actin 
have been shown to be phosphorylated [21,22]. 
It appears from our and others’ data that the 
crosslinking of gp 140, the C3d/EBV receptor 
(CR2), at the cell surface by probes such as F(ab)‘2 
anti-gp 140 [13], particle bound C3d [23] or inac- 
tivated EBV particles [24] leads to the enhance- 
ment of B lymphocyte proliferation. The level and 
the kinetics of CR2 phosphorylation in human B 
lymphocytes activated by these different probes 
are under analysis. 
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